falsefalse

My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC - Episode 1

Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

,

Panelists discuss how the treatment approach for a 67-year-old man with stage IIIB+ non–small cell lung cancer (NSCLC) awaiting mutation testing involves balancing the urgency of initiating therapy with the importance of molecular testing to guide targeted treatment decisions.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing
    EP. 2: Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy
    EP. 3: Testing Methodologies and Standards in Metastatic NSCLC
    EP. 4: Practical Considerations in Metastatic NSCLC: Access and Timing of Testing
    EP. 5: Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results
    EP. 6: Initial Approach to Management of RET-Positive NSCLC
    EP. 7: Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC
    EP. 8: Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC
    EP. 9: Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC
    EP. 10: Managing RET Inhibitor Treatment-Related Adverse Events
    EP. 11: Monitoring Patients With RET-Positive NSCLC
    EP. 12: Unmet Needs and Future Perspectives of RET-Positive NSCLC

    Related Content:

    My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC Video SeriesInsights
    Future Considerations for Treatment Sequencing in B-ALL
    Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center
    Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL
    x